Is a gallium-67 scan appropriate for diagnosing cardiac sarcoidosis?

Gallium-67 Scan for Cardiac Sarcoidosis

Gallium-67 scintigraphy is NOT recommended as a primary diagnostic modality for cardiac sarcoidosis due to its low sensitivity, despite having reasonable specificity. 1, 2

Preferred Diagnostic Approach

For patients with suspected cardiac involvement from extracardiac sarcoidosis, cardiac MRI with late gadolinium enhancement (CMR-LGE) should be performed first to obtain both diagnostic and prognostic information. 1

• CMR-LGE demonstrates direct histopathological correlation with cardiac sarcoidosis and predicts freedom from serious cardiac events for at least 3 years when negative. 1
• The extent of LGE correlates with risk of future major adverse cardiac events. 1

If CMR is unavailable or results are inconclusive, dedicated cardiac FDG-PET (with prolonged fasting) should be used instead of gallium-67 scanning. 1

Why Gallium-67 Falls Short

The 2020 American Thoracic Society guidelines explicitly acknowledge that gallium-67 has low sensitivity for detecting cardiac sarcoidosis, though it shows high uptake intensity that correlates with degree of inflammation. 2

• Research comparing gallium-67 to FDG-PET demonstrates dramatically inferior performance: gallium-67 sensitivity was only 15% versus 85% for FDG-PET, with accuracy of 42.8% versus 86.7%. 3
• Even with SPECT/CT fusion imaging to improve anatomic localization, gallium-67 achieved only 69% sensitivity and 79% specificity. 4

Limited Role for Gallium-67

Gallium-67 may have a narrow role in two specific scenarios:

1. Assessing response to corticosteroid therapy in patients with established cardiac sarcoidosis, where disappearance of gallium uptake can indicate treatment response. 5, 6, 7

2. Predicting corticosteroid responsiveness when combined with thallium-201 imaging—patients showing gallium-67 uptake alongside thallium-201 defects may respond better to steroids than those with thallium defects alone. 7

Practical Considerations

• FDG-PET requires prolonged fasting (adequate dietary preparation) to suppress normal myocardial glucose metabolism and improve diagnostic accuracy. 3
• The FDA label for gallium-67 acknowledges it cannot differentiate between tumor and acute inflammation, requiring additional diagnostic studies. 8
• Gallium-67 is included as a minor criterion in Japanese Ministry of Health and Welfare guidelines, but this reflects historical practice rather than optimal diagnostic performance. 3, 9

Screening Recommendations

For asymptomatic patients with extracardiac sarcoidosis, baseline ECG is recommended for screening, not gallium-67 scanning. 1

• Routine TTE or 24-hour Holter monitoring are not recommended for screening in asymptomatic patients. 1